Abstract | PURPOSE: PATIENTS AND METHODS: A neoadjuvant randomized phase II trial of LHRHa with AA was conducted in patients with localized high-risk PCa (N = 58). For the first 12 weeks, patients were randomly assigned to LHRHa versus LHRHa plus AA. After a research prostate biopsy, all patients received 12 additional weeks of LHRHa plus AA followed by prostatectomy. RESULTS: CONCLUSION: LHRHa plus AA treatment suppresses tissue androgens more effectively than LHRHa alone. Intensive intratumoral androgen suppression with LHRHa plus AA before prostatectomy for localized high-risk PCa may reduce tumor burden.
|
Authors | Mary-Ellen Taplin, Bruce Montgomery, Christopher J Logothetis, Glenn J Bubley, Jerome P Richie, Bruce L Dalkin, Martin G Sanda, John W Davis, Massimo Loda, Lawrence D True, Patricia Troncoso, Huihui Ye, Rosina T Lis, Brett T Marck, Alvin M Matsumoto, Steven P Balk, Elahe A Mostaghel, Trevor M Penning, Peter S Nelson, Wanling Xie, Zhenyang Jiang, Christopher M Haqq, Daniel Tamae, NamPhuong Tran, Weimin Peng, Thian Kheoh, Arturo Molina, Philip W Kantoff |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 32
Issue 33
Pg. 3705-15
(Nov 20 2014)
ISSN: 1527-7755 [Electronic] United States |
PMID | 25311217
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 by American Society of Clinical Oncology. |
Chemical References |
- AR protein, human
- Androgen Antagonists
- Androstadienes
- Receptors, Androgen
- Testosterone
- Prostate-Specific Antigen
- Leuprolide
- Abiraterone Acetate
|
Topics |
- Abiraterone Acetate
- Aged
- Androgen Antagonists
(therapeutic use)
- Androstadienes
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Humans
- Leuprolide
(administration & dosage, adverse effects)
- Male
- Middle Aged
- Neoadjuvant Therapy
- Prostate-Specific Antigen
(blood)
- Prostatectomy
- Prostatic Neoplasms
(blood, drug therapy, pathology)
- Receptors, Androgen
(analysis)
- Testosterone
(blood)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|